Paper · 21499862

Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.

Regine WF and 9 others. Ann Surg Oncol, 2011. Cited by 232 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Papers, record 21499862. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21499862

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.; PubMed
Journal: Ann Surg Oncol; PubMed
Year: 2011; PubMed
Publication types: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/21499862/; PubMed
DOI: https://doi.org/10.1245/s10434-011-1630-6; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC3548408/; PubMed
The journal: https://conductscience.org/library/journal-index/9420840; PubMed
Citations, by iCite: 232; iCite
Relative citation ratio, by iCite: 6.25; iCite
Revised in PubMed: 2025-05-29; PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Regine WF	William F
2	Winter KA	Kathryn A
3	Abrams R	Ross
4	Safran H	Howard
5	Hoffman JP	John P
6	Konski A	Andre
7	Benson AB	Al B
8	Macdonald JS	John S
9	Rich TA	Tyvin A
10	Willett CG	Christopher G

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Adenocarcinoma	Major topic
Antineoplastic Combined Chemotherapy Protocols	Major topic
Neoplasm Recurrence, Local	Major topic
Pancreatic Neoplasms	Major topic
Adult
Aged
Aged, 80 and over
Cohort Studies
Combined Modality Therapy
Deoxycytidine
Female
Fluorouracil
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Survival Rate
Treatment Outcome
Gemcitabine

Source PubMed

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
UL1 RR025741	NCRR NIH HHS	United States	UL1RR025741	PubMed and NIH	NIH RePORTER
U10 CA21661	NCI NIH HHS	United States	U10CA021661	PubMed and NIH	NIH RePORTER
U10 CA37422	NCI NIH HHS	United States	U10CA037422	PubMed and NIH	NIH RePORTER
U10 CA037422	NCI NIH HHS	United States	U10CA037422	PubMed and NIH	NIH RePORTER
U10 CA021661	NCI NIH HHS	United States	U10CA021661	PubMed and NIH	NIH RePORTER

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT00003216	Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas	Results		ClinicalTrials.gov
NCT04289792	Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer	Background		ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment in	21,384,245	Adjuvant therapy for pancreatic cancer: a logical strategy in search of progress.	https://conductscience.org/library/papers/21384245

Source PubMed

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	9,367,020	Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.	Ann Surg Oncol	1997	https://conductscience.org/library/papers/9367020	PubMed
2	4,015,380	Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.	Arch Surg	1985	https://conductscience.org/library/papers/4015380	PubMed
3	3,326,653	Cancer of the pancreas. 50 years of surgery.	Cancer	1987	https://conductscience.org/library/papers/3326653	PubMed
4	15,028,824	A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.	N Engl J Med	2004	https://conductscience.org/library/papers/15028824	PubMed
5	5,910,392	Evaluation of survival data and two new rank order statistics arising in its consideration.	Cancer Chemother Rep	1966	https://conductscience.org/library/papers/5910392	PubMed
6	1,260,670	Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy.	Cancer	1976	https://conductscience.org/library/papers/1260670	PubMed
7	4,612,056	The randomization and stratification of patients to clinical trials.	J Chronic Dis	1974	https://conductscience.org/library/papers/4612056	PubMed
8	18,319,412	Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.	JAMA	2008	https://conductscience.org/library/papers/18319412	PubMed
9	9,193,189	Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.	Ann Surg	1997	https://conductscience.org/library/papers/9193189	PubMed
10	17,452,677	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	J Clin Oncol	2007	https://conductscience.org/library/papers/17452677	PubMed

1 to 10 of 18

See all 18 references

Cited by131

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 232 citations.

PMID	Title	Journal	Year	In Papers	Source
42,782,866	Practical Considerations in the Radiotherapy Treatment Planning for SBRT Pancreas Program.	Curr Oncol	2026	https://conductscience.org/library/papers/42782866	PubMed
42,738,277	Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma-Past, Present, and Future.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42738277	PubMed
42,592,360	Exploring the role of immunotherapy and radiotherapy in the adjuvant landscape of resected pancreatic cancer.	Transl Gastroenterol Hepatol	2026	https://conductscience.org/library/papers/42592360	PubMed
41,514,607	Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making.	Cancers (Basel)	2025	https://conductscience.org/library/papers/41514607	PubMed
41,436,429	FUT2 enhances anti-tumor immunity in pancreatic cancer radiotherapy by driving FBXO2-mediated degradation of NR2F2.	Cell Death Dis	2025	https://conductscience.org/library/papers/41436429	PubMed
41,365,129	Radiotherapy in the management of PDAC, from past to present.	Transl Oncol	2026	https://conductscience.org/library/papers/41365129	PubMed
41,345,265	New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer.	Br J Cancer	2026	https://conductscience.org/library/papers/41345265	PubMed
40,935,440	Intraoperative Radiation for Pancreatic Cancer.	Semin Radiat Oncol	2025	https://conductscience.org/library/papers/40935440	PubMed
40,662,364	Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer.	J Clin Invest	2025	https://conductscience.org/library/papers/40662364	PubMed
40,182,139	Pancreatic Cancer: Pathogenesis and Clinical Studies.	MedComm (2020)	2025	https://conductscience.org/library/papers/40182139	PubMed

1 to 10 of 131

See all 131 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
FLUOROURACIL	CHEMBL185	Results	1	https://conductscience.org/library/drugs/CHEMBL185	ChEMBL
GEMCITABINE	CHEMBL888	Results	1	https://conductscience.org/library/drugs/CHEMBL888	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21499862

GET https://conductscience.org/api/papers/v1/21499862/cited_by?page=2

API reference For AI assistants